CA2662101C - Candidates against infection - Google Patents

Candidates against infection Download PDF

Info

Publication number
CA2662101C
CA2662101C CA2662101A CA2662101A CA2662101C CA 2662101 C CA2662101 C CA 2662101C CA 2662101 A CA2662101 A CA 2662101A CA 2662101 A CA2662101 A CA 2662101A CA 2662101 C CA2662101 C CA 2662101C
Authority
CA
Canada
Prior art keywords
plasminogen
mice
bacterial
plg
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2662101A
Other languages
English (en)
French (fr)
Other versions
CA2662101A1 (en
Inventor
Tor Ny
Jinan Li
Yongzhi Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omnio Healer AB
Original Assignee
Omnio Healer AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omnio Healer AB filed Critical Omnio Healer AB
Publication of CA2662101A1 publication Critical patent/CA2662101A1/en
Application granted granted Critical
Publication of CA2662101C publication Critical patent/CA2662101C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
CA2662101A 2006-08-28 2007-08-28 Candidates against infection Expired - Fee Related CA2662101C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82366506P 2006-08-28 2006-08-28
US60/823,665 2006-08-28
PCT/SE2007/050585 WO2008026999A2 (en) 2006-08-28 2007-08-28 Candidates against infection

Publications (2)

Publication Number Publication Date
CA2662101A1 CA2662101A1 (en) 2008-03-06
CA2662101C true CA2662101C (en) 2015-07-07

Family

ID=39136397

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2662101A Expired - Fee Related CA2662101C (en) 2006-08-28 2007-08-28 Candidates against infection

Country Status (12)

Country Link
US (3) US8318661B2 (cg-RX-API-DMAC7.html)
EP (1) EP2056864B1 (cg-RX-API-DMAC7.html)
JP (1) JP5566105B2 (cg-RX-API-DMAC7.html)
KR (1) KR101517626B1 (cg-RX-API-DMAC7.html)
CN (2) CN101573134B (cg-RX-API-DMAC7.html)
AU (1) AU2007290881B2 (cg-RX-API-DMAC7.html)
CA (1) CA2662101C (cg-RX-API-DMAC7.html)
DK (1) DK2056864T3 (cg-RX-API-DMAC7.html)
EA (1) EA016250B1 (cg-RX-API-DMAC7.html)
ES (1) ES2451015T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009002226A (cg-RX-API-DMAC7.html)
WO (1) WO2008026999A2 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
AU2007290882B2 (en) 2006-08-28 2013-02-21 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
RU2421192C1 (ru) * 2010-03-09 2011-06-20 Винера Гумаровна Нафикова Способ лечения хронического бактериального конъюнктивита
PL2598165T3 (pl) * 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
CN102507707B (zh) * 2011-10-12 2015-10-21 山东大学 一种检测龈沟液中蛋白裂解酶含量的方法
CN106456740B (zh) 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
CN106890321A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防和治疗宫颈糜烂的方法
EP3395355B1 (en) * 2015-12-18 2026-03-04 Talengen International Limited Plasminogen for use in treating cervical erosion
EP3395354B1 (en) * 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
TWI677347B (zh) * 2015-12-18 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療肝組織損傷及其相關病症的方法
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドTalengen International Limited 糖尿病網膜症を予防または治療するための方法
CA3008466C (en) * 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
JP7213552B2 (ja) * 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
CN108210904A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 治疗动脉粥样硬化及其并发症的药物及其用途
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
TWI750189B (zh) 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
CA3047170A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury
WO2018107689A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂质肾损伤的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN107496911A (zh) * 2017-10-20 2017-12-22 滕敏子 一种外科手术后用于防肿胀、抗感染的愈合剂
CN113164564A (zh) * 2018-11-19 2021-07-23 诺尔玛克Ip股份有限公司 用于治疗或预防心内膜炎的安克洛酶
CN114174528B (zh) * 2019-08-07 2025-02-21 学校法人东京齿科大学 判别方法、荧光测定装置和检查剂
CN111742887A (zh) * 2019-12-19 2020-10-09 广西医科大学第一附属医院 放疗后分泌性中耳炎树鼩模型的建立方法
EP4094776A4 (en) * 2020-02-11 2023-05-17 Talengen International Limited METHODS AND MEDICATIONS FOR THE TREATMENT OF VIRAL PENMONIA
WO2021180068A1 (zh) * 2020-03-09 2021-09-16 泰伦基国际有限公司 一种治疗2019新型冠状病毒引发疾病的方法和药物
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN115845036B (zh) * 2023-02-20 2023-05-09 滨州益洁口腔有限公司 用于口腔种植体牙龈组织的蛋白酶及制备方法
JP2026526789A (ja) * 2023-07-20 2026-08-10 カトリック ユニヴェルシテット ルーヴェン ブドウ球菌性膿瘍の治療

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023143A (en) * 1959-10-14 1962-02-27 American Cyanamid Co Process for preparing a veterinary composition
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5792835A (en) 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
US5397578A (en) * 1994-03-29 1995-03-14 Tovarischestvo S Ogranichennoi Otvetstvennostiju "Taurus" Method of treatment of chronic purulent inflammations of ear in children
US6372473B1 (en) 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US6420622B1 (en) * 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
AU5390699A (en) 1998-07-24 2000-02-14 Pharmacal Biotechnologies, Inc. Osseous tissue reconstruction system and method
WO2000051538A1 (en) 1999-03-01 2000-09-08 Uab Research Foundation Porous tissue scaffolding materials and uses thereof
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20030206906A1 (en) 2001-11-26 2003-11-06 Genentech, Inc. Catheter composition and uses thereof
MXPA04007585A (es) * 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
CN1420126A (zh) 2002-07-10 2003-05-28 牛勃 一种重组人纤溶酶原Kringle5突变体蛋白rhPK-5的制备方法
AU2007290882B2 (en) 2006-08-28 2013-02-21 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health

Also Published As

Publication number Publication date
CA2662101A1 (en) 2008-03-06
KR101517626B1 (ko) 2015-05-07
CN101563100B (zh) 2013-08-07
JP5566105B2 (ja) 2014-08-06
EP2056864B1 (en) 2013-12-11
US20100099600A1 (en) 2010-04-22
ES2451015T3 (es) 2014-03-26
US10729750B2 (en) 2020-08-04
US20160243204A1 (en) 2016-08-25
EA200970233A1 (ru) 2009-08-28
CN101573134B (zh) 2013-03-06
US8318661B2 (en) 2012-11-27
EP2056864A4 (en) 2012-01-25
WO2008026999A3 (en) 2008-05-22
KR20090059122A (ko) 2009-06-10
US20130149321A1 (en) 2013-06-13
JP2010502600A (ja) 2010-01-28
EA016250B1 (ru) 2012-03-30
WO2008026999A2 (en) 2008-03-06
AU2007290881A1 (en) 2008-03-06
CN101563100A (zh) 2009-10-21
CN101573134A (zh) 2009-11-04
EP2056864A2 (en) 2009-05-13
DK2056864T3 (en) 2014-03-10
MX2009002226A (es) 2009-09-07
AU2007290881B2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
US10729750B2 (en) Candidates against infection
Glasser et al. Mechanisms of lung fibrosis resolution
Chung et al. Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors
Zhu et al. Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation
ES2279001T3 (es) Uso de plasminogeno para promover la cicatrizacion de la perforacion de la membrana del timpano.
DK2056865T3 (en) Hitherto unknown medicinal products for the prevention and treatment of gum disease, improvement of healing of gums in the gums and promotion of dental and oral health
Zhang et al. Evaluation of breviscapine on prevention of experimentally induced abdominal adhesions in rats
Litwiniuk et al. Potential role of metalloproteinase inhibitors from radiation-sterilized amnion dressings in the healing of venous leg ulcers
Gabre et al. Activated protein C accelerates venous thrombus resolution through heme oxygenase‐1 induction
JP2020023519A (ja) 異常な皮膚瘢痕化の治療
Miao et al. Staphylococcus aureus on the effect of expression of MMPs/TIMPs and uPA system in bovine mammary fibroblasts
JP2009528339A (ja) ペプチド及びその使用
HK1136204A (en) Candidates against infection
CN108463235A (zh) 一种用于预防和治疗宫颈糜烂的方法
Oliveira et al. Lack of matrix metalloproteinase-9 impairs neutrophil degranulation and prevents liver damage in mice
JP2013532649A (ja) 初期免疫防御において新規な機能を発揮する先祖セリンプロテアーゼ凝固カスケード
CN101541829A (zh) 来自丝光绿蝇的胰凝乳蛋白酶及其在治疗伤口中的用途
Hendel Granzyme B in vascular remodeling and pathological angiogenesis
Kostamo Microbiological, environmental and proteolytic aspects in chronic rhinosinusitis with nasal polyposis
Blain et al. British Society for Matrix Biology Meeting, Norwich, 3–4 September 2001
Meijer Targeting growth rate of abdominal aortic aneurysm
HK1134788B (en) Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210830